Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse — A model mimicking inflammatory bowel disease
- 1 February 2014
- journal article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 8 (2) , 147-160
Abstract
In inflammatory bowel disease a defective mucosal barrier, a dysregulated immune response and an excessive reactivity against the gut microbiota are assumed to cause a breakdown of the intestinal homeostasis and lead to chronic inflammation. Piroxicam treatment is a method for induction of colitis in IL-10 k.o. mice, which integrates a dysfunction of both the intestinal barrier and the immune system. However, the translational value of this model has not been thoroughly clarified. To characterise the piroxicam-accelerated colitis (PAC) IL-10 k.o. model with respect to clinical features, pathogenic mechanisms and its ability to respond to existing therapies. The PAC IL-10k.o. model was established on a C57BL/6J background and the clinical manifestations, immunological mechanisms and efficacy of ampicillin and anti-IL-12/23p40 treatment were assessed. The PAC IL-10 k.o. mice developed weight loss and diarrhoea, and colonoscopy revealed a thickened granulomatous mucosa. Histological evaluation of ileum and colon showed Crohn's disease-like changes with pronounced hyperplasia and focal transmural inflammation. Ileitis was also observed in piroxicam treated wild type mice. The total number of neutrophils, monocytes and natural killer cells was elevated in the blood compared to IL-10 k.o. and wild type mice, indicating a role of the innate immune system in the pathogenesis. These findings were supported by analyses of the intestinal cytokine profile. Ampicillin and anti-IL-12/23p40 treatment significantly suppressed disease in the model. The PAC IL-10 k.o. model resembles several features of Crohn's disease and could be a useful in vivo model in preclinical research.Keywords
Funding Information
- Novo Nordisk — LIFE In Vivo Pharmacology Centre (LIFEPHARM)
- Department of Immunopharmacology, Novo Nordisk A/S
This publication has 56 references indexed in Scilit:
- Pharmacological intervention studies using mouse models of the inflammatory bowel diseasesInflammatory Bowel Diseases, 2011
- Colitis and Intestinal Inflammation in IL10 Mice Results From IL-13Rα2–Mediated Attenuation of IL-13 ActivityGastroenterology, 2011
- Inflammatory Bowel DiseaseAnnual Review of Immunology, 2010
- Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 ReceptorNew England Journal of Medicine, 2009
- Evaluation of animal models of neurobehavioral disordersBehavioral and Brain Functions, 2009
- Bacterial-mucosal interactions in inflammatory bowel disease—an alliance gone badAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's diseaseNature Genetics, 2008
- IL-23 plays a key role inHelicobacter hepaticus–induced T cell–dependent colitisJournal of Experimental Medicine, 2006
- IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6Journal of Clinical Investigation, 2006
- Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.Journal of Clinical Investigation, 1996